• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care
Prostate Cancer : Episode 3

Episode 3 - Radium-223 for the Treatment of CRPC

Video

In addition to cytotoxic chemotherapy, immunotherapy, and oral agents that target the androgen pathway, David Crawford, MD, discusses radium-223 as a therapeutic option for the treatment of castration-resistant prostate cancer (CRPC).

Dr Crawford cites the ALSYMPCA clinical trial and explains how the trial tested radium-223 and found that the drug demonstrated several benefits to patients with CRPC. Benefits included increased survival rates, decreased instances of overall pain, and lower numbers of symptomatic skeletal events and fractures, as well as lessened the need for treatment with surgery or radiation.


Related Videos
Jaime Almandoz, MD, MBA
Martin Edelman, MD
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Pierluigi Porcu, MD
Image credit: Medical technology and futuristic concept. Doctor hologram modern virtual screen interface | SOMKID - stock.adobe.com
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Elizabeth Grush, MBA
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Erin Weber, MS
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.